Age of Blood in Sickle Cell Transfusion -The Effects of Phosphotidylserine Expression on Older Red Cell Units in Adults With Sickle Cell Disease

Study point of contact

Steven Frymark
414-937-6814
[email protected]
Matthew Karafin, MD
414-937-6809
[email protected]

Locations

2 United States sites

Age

16 to 45 Years

Phase

Phase 2/Phase 3

Study type

Interventional

Gender

All

Interventions

Biological

Compensation

Unknown

About the study

The Investigators hypothesize that older red cell units trigger phagocytosis and activation
of circulating macrophages with a downstream immunomodulatory cascade and release of excess
Non Transferrin Bound Iron(NTBI) that leads to increased rates of infection in adults with
Sickle Cell Disease(SCD). To test this hypothesis, the study staff will perform a randomized
prospective clinical trial. In aim 1, the study staff will determine the biochemical
differences between ≥30 day-old versus ≤10 day-old units. In aim 2, the study staff will
determine the physiologic effects of the transfused blood in a patient with SCD. Lastly, in
aim 3, the study staff will explore the clinical implications of receiving older red cells
over a 3 month period.

participation requirements

1. age 16 to 45 years

2. Hemoglobin SS/Hemoglobin Sβ-thalassemia0

3. on chronic red cell transfusion therapy

4. outpatient at the time of transfusion

participation restrictions

1. history of reactions to transfusion therapy that cannot be adequately managed by
antihistamines

2. ≥2 red cell alloantibodies

3. participation in another therapeutic trial for SCD

4. pregnant

5. HIV positive

6. uncontrolled inter-current illness, or psychiatric illness/social situations that
would limit compliance with study requirements.

Locations

  • Atlanta, Georgia, United States, Emory University, 30322 [Not yet recruiting]
  • Milwaukee, Wisconsin, United States, Versiti Wisconsin, 53226 [Recruiting]